Q4 2025 Johnson & Johnson Earnings Call Transcript
Key Points
- Johnson & Johnson (JNJ) reported strong full-year results for 2025, with operational sales growth of 5.3%, driven by robust performance across its key business segments.
- The company achieved significant milestones in its pharmaceutical business, with full-year sales exceeding $60 billion for the first time and 13 brands growing double digits.
- In Oncology, Johnson & Johnson (JNJ) delivered 21% operational sales growth, with DARZALEX achieving over $14 billion in annual sales and CARVYKTI becoming the leading CAR T-cell therapy in multiple myeloma.
- The MedTech segment showed strong performance, with operational sales growth of 5.4% and significant contributions from Cardiovascular and Vision segments.
- Johnson & Johnson (JNJ) has a robust pipeline with 51 approvals and 32 submissions in 2025, positioning the company for accelerated growth in 2026 and beyond.
- The company faced a significant headwind from STELARA, impacting sales growth by approximately 620 basis points for the full year.
- There are ongoing challenges in the MedTech market, including competitive pressures in energy and endo cutters, as well as volume-based procurement in China.
- Johnson & Johnson (JNJ) is dealing with litigation related to talc, which could pose financial and reputational risks despite the company's strategy to aggressively fight these claims.
- The Neuroscience segment, while showing growth, faces competitive pressures and the need for continued innovation to maintain momentum.
- The company anticipates generic impact for both SIMPONI and [Upsummit] to begin in 2026, which could affect sales in the innovative medicine segment.
Good morning and welcome to Johnson & Johnson's fourth quarter 2025 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being recorded.
If anyone has any objections and may disconnect at this time. (Operator Instructions) I will now turn the conference call over to Johnson & Johnson. You may begin.
Hello everyone, this is Darren Snellgrove, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of business results for the fourth quarter and full year 2025 and our financial outlook for 2026.
First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
